Counterfeiting, Compliance, and Controls

Published on: 
Pharmaceutical Technology, Pharmaceutical Technology-09-02-2003, Volume 27, Issue 9

FDA and manufacturers seek to curb drug counterfeiting while legislators consider liberalizing drug importing policies to cut pharmaceutical costs.

Related Content:

Regulatory Oversight and ComplianceSupply ChainManufacturingPharmaceutical Technology-09-02-2003
INTERPHEX 2025: Advanced Flow Sensor Technologies Enable More Accurate Measurement
Recapping INTERPHEX 2025: Pharma Looks Toward the Future
N-Nitrosamine Impurities and FDA’s Recommendations for Acceptable Intake Limits